Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Gilead Sciences Inc (NASDAQ:GILD)

77.86
Delayed Data
As of Sep 29
 -1.11 / -1.41%
Today’s Change
76.67
Today|||52-Week Range
111.11
-23.06%
Year-to-Date
England's chief medic says NHS should fund drug to prevent HIV
7:30am / FT.com - Paid Partner Content
Sentiments About the Market, Oil, Retailers: Jim Cramer's Views
Sep 26 / TheStreet.com - Paid Partner Content
Gilead Sciences Stock Downgraded: 3 Things You Need to Know
Sep 28 / MotleyFool.com - Paid Partner Content
Is This Tiny Company the Best Pharmacy Stock to Buy?
Sep 24 / MotleyFool.com - Paid Partner Content
Biotech Stock Roundup: Amgen's Kyprolis Disappoints, Array Up on Cancer Data
Sep 28 / Zacks.com - Paid Partner Content
3 Dirt-Cheap Dividend Stocks You Can Buy Right Now
Sep 24 / MotleyFool.com - Paid Partner Content
Why Cash Is King for Biotech Stocks
Sep 27 / MotleyFool.com - Paid Partner Content
Dow 30 Stock Roundup: Microsoft Rewards Shareholders; GE Wins $1.9B Nuclear Power Con...
Sep 23 / Zacks.com - Paid Partner Content
Jim Cramer -- Gilead Needs to Make an Acquisition
Sep 27 / TheStreet.com - Paid Partner Content
Gilead (GILD) Stock Higher, Citigroup: Hepatitis C Drug Sales Improving
Sep 23 / TheStreet.com - Paid Partner Content
Gilead (GILD) Stock Falls on Ratings Downgrade
Sep 27 / TheStreet.com - Paid Partner Content
Gilead Sciences Inc.'s Biggest Win in 2016 So Far
Sep 22 / MotleyFool.com - Paid Partner Content
Analysts' Actions -- AutoZone, Eli Lilly, J.M. Smucker, Toll Brothers and More
Sep 27 / TheStreet.com - Paid Partner Content
The Pros and Cons of Buying Gilead Sciences Stock
Sep 22 / MotleyFool.com - Paid Partner Content
5 Safe Stocks to Buy Today
Sep 27 / MotleyFool.com - Paid Partner Content
Gilead to Stop GS-5745 Development for Ulcerative Colitis
Sep 22 / Zacks.com - Paid Partner Content
Wall Street Sells Off on Worries Over Clinton-Trump Showdown
Sep 26 / TheStreet.com - Paid Partner Content
Is Galectin The Next Takeover Target for the Biotech World?
Sep 22 / Zacks.com - Paid Partner Content
This Hated Pharma Stock Has A Bright Future
Sep 26 / StreetAuthority - Paid Partner Content
Stock Market News for September 21, 2016
Sep 21 / Zacks.com - Paid Partner Content
Biotech ETFs May Be a Prescription for Investment Success, Especially If Trump Become...
Sep 26 / TheStreet.com - Paid Partner Content
Allergan Buys NASH Therapy Maker Tobira at Huge Premium
Sep 21 / Zacks.com - Paid Partner Content
Will Gilead (GILD) Stock Be Helped by Positive Crohn's Drug Results?
Sep 26 / TheStreet.com - Paid Partner Content
How Safe Is Gilead Sciences Inc. and Its Dividend?
Sep 20 / MotleyFool.com - Paid Partner Content
Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies
Sep 26 / TheStreet.com - Paid Partner Content
How Risky Is Gilead Sciences Inc.?
Sep 18 / MotleyFool.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Deutsche Bank, Apple, Therapeutics, Allergan and G...
Sep 26 / Zacks.com - Paid Partner Content
Takeda earmarks $15bn for US pharma acquisitions
Sep 13 / FT.com - Paid Partner Content